Optimizing the Utility of Ultrasound for Assessment and Treatment of the Spastic Muscle: Practical Clinical Pearls

Topic Spasticity
Main Speaker Rajiv Reebye Canada
Co Speakers Ève Boissonnault Canada, Anton Pick UK, Stefano Carda Switzerland, Omar Khan 
Attendees
Extra Fees Supported par MerZ

Ultrasound (US) is an important tool for performing chemodenervation and diagnostic nerve blocks in the treatment of spasticity.

The role of ultrasound in spasticity management has been well discussed literature. (Alter & Karp, 2017; Winston et al., 2023) In addition, US guidance may help clinicians in the long-term assessment and follow-up of muscle quality. (Moreta et al., 2020) There is great interest amongst physicians specialized in spastic motor disorders regarding the ability to differentiate the degree of echo intensity in patients with an upper motoneuron pathology due to recent literature suggesting that echogenicity has the potential to influence response to spasticity treatment, including response to botulinum toxin injections.

(Picelli et al., 2012; Hara et al., 2018) Our group of physiatrists with expertise in spasticity management has been collaborating and contributing to the literature on the use of US for spasticity assessment and management over the last few years.

(Francisco et al., 2021; Lagnau et al., 2021; Winston et al., 2023; Kassam et al., 2023; Boissonnault et al., 2024; Heslot et al., 2024; McRae et al. 2024) The focus of this workshop is to provide clinical pearls to enhance the use of ultrasound in the research and clinical settings.